Assessment cycle 2025 Q1 — page 2
Documents ratified in the 2025 Q1 assessment cycle, which ran from 1 January 2025 to 31 March 2025 and was ratified on 18 March 2025.
Documents ratified
-
Randomised, double-blind, placebo-controlled, phase 3 study of Orforglipron in obesity over 72 weeks. Primary result: The Institute holds a headline result indicating a…
Moderate21 Feb 2026 -
Randomised, double-blind, placebo-controlled, phase 3 study of Orforglipron in obesity and type 2 diabetes over 72 weeks. The Institute holds no reported primary result…
09 Sep 2025 -
Randomised, double-blind, placebo-controlled, phase 3 study of Orforglipron in type 2 diabetes over 40 weeks. The Institute holds no reported primary result for this…
03 Apr 2026 -
Randomised, double-blind, active-controlled, phase 3 study of Orforglipron in type 2 diabetes over 52 weeks. The Institute holds no reported primary result for this…
18 Mar 2026 -
Randomised, double-blind, placebo-controlled, phase 3 study of CagriSema (cagrilintide with semaglutide) in obesity randomising 3,417 participants over 68 weeks. Primary…
Moderate12 Jan 2026 -
Randomised, double-blind, placebo-controlled, phase 3 study of CagriSema (cagrilintide with semaglutide) in obesity and type 2 diabetes randomising 1,206 participants…
Moderate16 Jun 2025 -
Randomised, double-blind, placebo-controlled, phase 3 study of Mazdutide in obesity randomising 610 participants over 48 weeks. Primary result: Mean change −14.0 % at 6…
Moderate09 Jul 2025 -
Randomised, double-blind, placebo-controlled, phase 3 study of Ecnoglutide in obesity randomising 664 participants over 48 weeks. Primary result: Mean change −13.2 % at…
Low01 Nov 2025 -
Randomised, double-blind, placebo-controlled, phase 3 study of Ecnoglutide in type 2 diabetes over 52 weeks. The Institute holds no reported primary result for this…
17 Jul 2025 -
Randomised, double-blind, placebo-controlled, phase 3 study of Exenatide in cognition randomising 194 participants over 96 weeks. Primary result: No significant…
Moderate16 Aug 2025 -
Randomised, double-blind, placebo-controlled, phase 3 study of Tirzepatide in knee osteoarthritis and obesity over as stated in the parent protocol. The Institute holds…
Very low13 May 2026 -
Phase 1 ascending dose, phase 1 study of Tirzepatide in cardiovascular and type 2 diabetes over as stated in the parent protocol. The Institute holds no reported primary…
Very low14 Sep 2025 -
Randomised, double-blind, placebo-controlled, phase 3 study of Orforglipron in obesity over as stated in the parent protocol. The Institute holds no reported primary…
Very low25 Jul 2025 -
Randomised, double-blind, placebo-controlled, phase 3 study of Orforglipron in obesity and type 2 diabetes over as stated in the parent protocol. The Institute holds no…
Very low22 May 2026 -
Randomised, double-blind, placebo-controlled, phase 3 study of Orforglipron in type 2 diabetes over as stated in the parent protocol. The Institute holds no reported…
Very low23 Feb 2026 -
Randomised, double-blind, placebo-controlled, phase 3 study of Orforglipron in type 2 diabetes over as stated in the parent protocol. The Institute holds no reported…
Very low23 Feb 2026 -
Observational, phase 3 study of CagriSema (cagrilintide with semaglutide) in obesity over as stated in the parent protocol. The Institute holds no reported primary…
Very low18 Jan 2026 -
Single-arm open-label, phase 3 study of CagriSema (cagrilintide with semaglutide) in obesity and type 2 diabetes over open-label extension of the parent trial. The…
Very low24 Dec 2025 -
Phase 1 ascending dose, phase 1 study of Semaglutide, oral in cardiovascular and type 2 diabetes over as stated in the parent protocol. The Institute holds no reported…
Very low14 Jul 2025 -
Phase 1 ascending dose, phase 1 study of Semaglutide in mash over as stated in the parent protocol. The Institute holds no reported primary result for this record and…
Very low10 Mar 2026 -
Randomised, double-blind, placebo-controlled, phase 3 study of Semaglutide in peripheral arterial disease and type 2 diabetes over as stated in the parent protocol. The…
Very low09 Dec 2025 -
Randomised, double-blind, placebo-controlled, phase 3 study of Mazdutide in obesity over as stated in the parent protocol. The Institute holds no reported primary result…
Very low28 Feb 2026 -
Randomised, double-blind, placebo-controlled, phase 3 study of Ecnoglutide in obesity over as stated in the parent protocol. The Institute holds no reported primary…
Very low16 Apr 2026 -
Randomised, double-blind, placebo-controlled, phase 3 study of Ecnoglutide in type 2 diabetes over as stated in the parent protocol. The Institute holds no reported…
Very low26 Aug 2025 -
Randomised crossover, phase 1 study of Exenatide in cognition over as stated in the parent protocol. The Institute holds no reported primary result for this record and…
Very low03 Mar 2026 -
Randomised, double-blind, placebo-controlled, phase 3 study of Tirzepatide in knee osteoarthritis and obesity over as stated in the parent protocol. The Institute holds…
Very low30 Jul 2025 -
Phase 1 ascending dose, phase 1 study of Tirzepatide in cardiovascular and type 2 diabetes over as stated in the parent protocol. The Institute holds no reported primary…
Very low21 Dec 2025 -
Single-arm open-label, phase 3 study of Orforglipron in obesity and type 2 diabetes over open-label extension of the parent trial. The Institute holds no reported…
Very low23 May 2025 -
Randomised, double-blind, placebo-controlled, phase 3 study of Orforglipron in type 2 diabetes over as stated in the parent protocol. The Institute holds no reported…
Very low03 Apr 2026 -
Single-arm open-label, phase 3 study of Orforglipron in type 2 diabetes over open-label extension of the parent trial. The Institute holds no reported primary result for…
Very low21 Feb 2026 -
Randomised, double-blind, placebo-controlled, phase 3 study of CagriSema (cagrilintide with semaglutide) in obesity and type 2 diabetes over as stated in the parent…
Very low15 Oct 2025 -
Phase 1 ascending dose, phase 1 study of Semaglutide, oral in cardiovascular and type 2 diabetes over as stated in the parent protocol. The Institute holds no reported…
Very low03 Jul 2025 -
Phase 1 ascending dose, phase 1 study of Semaglutide in mash over as stated in the parent protocol. The Institute holds no reported primary result for this record and…
Very low08 Sep 2025 -
Randomised, double-blind, placebo-controlled, phase 3 study of Semaglutide in peripheral arterial disease and type 2 diabetes over as stated in the parent protocol. The…
Very low23 May 2025 -
Randomised, double-blind, placebo-controlled, phase 3 study of Mazdutide in obesity over as stated in the parent protocol. The Institute holds no reported primary result…
Very low14 Jun 2025 -
Randomised, double-blind, placebo-controlled, phase 3 study of Ecnoglutide in obesity over as stated in the parent protocol. The Institute holds no reported primary…
Very low08 Jul 2025 -
Single-arm open-label, phase 3 study of Ecnoglutide in type 2 diabetes over open-label extension of the parent trial. The Institute holds no reported primary result for…
Very low26 Sep 2025 -
Phase 1 ascending dose, phase 1 study of Exenatide in cognition over as stated in the parent protocol. The Institute holds no reported primary result for this record and…
Very low25 Jun 2025 -
Phase 1 ascending dose, phase 1 study of Tirzepatide in obesity over as stated in the parent protocol. The Institute holds no reported primary result for this record and…
Very low14 Jun 2025 -
Randomised, double-blind, placebo-controlled, phase 3 study of Orforglipron in type 2 diabetes over as stated in the parent protocol. The Institute holds no reported…
Very low18 Jan 2026
page 2 of 3